Tau tangles are closely linked to Alzheimer’s disease progression. But the tau species associated with these aggregates are present at exceptionally low levels in blood, making them difficult to measure.
Spear Bio has introduced the first commercially available singleplex immunoassay for plasma eMTBR-Tau. This Friday, join Dr. Thomas Karikari, Associate Professor of Psychiatry at the University of Pittsburgh School of Medicine, and Dr. Tracy Liu, Director, Product Management at Spear Bio, to explore the science and research potential of this emerging biomarker.
Improve Tau tangle detection with emerging plasma eMTBR-Tau
Friday, October 2, 2026
11 am EDT / 4 pm BST / 5 pm CEST
In this webinar, you will learn:
- What eMTBR-Tau may reveal about tau tangle pathology and how it differs from established plasma pTau biomarkers
- How SPEAR ultrasensitive immunoassay technology enables measurement of low-abundance eMTBR-Tau in plasma
- What results from amyloid- and tau-PET–characterized research cohorts suggest about its potential applications
If you’re unable to attend live, register to receive the on-demand recording after the event.
Register Now
Spear Bio launches next generation ultrasensitive immunoassay solution SPEAR UltraDetect™ to transform neurodegenerative disease research